Premium
Synthesis and in vivo behavior of a copper‐64‐labeled dithiosemicarbazone derivative coupled to a dihydropyridine carrier
Author(s) -
Saji Hideo,
Saiga Akihiko,
Iida Yasuhiko,
Magata Yasuhiro,
Yokoyama Akira
Publication year - 1993
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580330207
Subject(s) - chemistry , pyridinium , in vivo , derivative (finance) , reducing agent , radiochemistry , copper , nuclear chemistry , positron emission tomography , medicinal chemistry , nuclear medicine , organic chemistry , medicine , microbiology and biotechnology , financial economics , economics , biology
The dihyropyridine ⇄ pyridinium salt redox delivery system was used to develop a perfusion agent that could be labeled with a generator‐produced positron emitter 62 Cu. A 64 Cu‐labeled dithiosemicarbazone (DTS) molecule attached to a dihyropyridine carrier (PDTS‐DHC) was synthesized by the simple mixing of 64 Cu acetate and Zn‐PDTS‐DHC. The latter was prepared by dithionite reduction of the Zn complex of a corresponding pyridinum precursor (PDTS‐QC + ). When injected into mice, 64 Cu‐PDTS‐DHC showed a high myocardial uptake and high heart‐to‐blood and heart‐to‐lung ratios. These results demonstrate that it may be possible to develop 62 Cu‐PDTS‐DHC compounds as radiopharmaceuticals for myocardial perfusion studies using positron emission tomography.